Related Experiment Videos
Oxaliplatin in colorectal cancer: current studies
1Mayo Clinic, Rochester, Minnesota, USA. goldberg.richard@mayo.edu
Oncology (Williston Park, N.Y.)
|February 24, 2001
Summary
Oxaliplatin shows promise as a chemotherapy for metastatic colorectal cancer, particularly in combination with fluorouracil/leucovorin. Ongoing trials are defining its optimal use and safety in various treatment settings.
Area of Science:
- Oncology
- Pharmacology
Background:
- Oxaliplatin is a third-generation platinum derivative showing promise for metastatic colorectal cancer.
- Preclinical and early clinical data suggest oxaliplatin's efficacy, especially in combination with fluorouracil (5-FU)/leucovorin.
Purpose of the Study:
- To evaluate the therapeutic roles and optimal regimens of oxaliplatin in advanced colorectal cancer.
- To define the efficacy and safety of oxaliplatin-based chemotherapy in various patient populations.
Main Methods:
- Ongoing clinical trials, including NCCTG N9741 and N9841, and NSABP C-07.
- Investigating oxaliplatin as monotherapy, in combination with 5-FU/leucovorin, and as neoadjuvant therapy.
Main Results:
- Oxaliplatin demonstrated clear activity as monotherapy and in combination regimens.
- Neoadjuvant oxaliplatin therapy enabled potentially curative hepatic resection in some patients with unresectable liver metastases.
- Oxaliplatin exhibited a reasonable safety profile in clinical trials.
Conclusions:
- Oxaliplatin is a promising agent for advanced colorectal cancer, with ongoing research to optimize its use.
- Combination therapy with 5-FU/leucovorin and other agents is under active investigation.
- Oxaliplatin holds potential for neoadjuvant treatment and adjuvant settings in colorectal cancer.